EM Microelectronic is a semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits (IC) for battery-operated and field-powered applications across diverse consumer and automotive industries. | EM Microelectronic is a semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits for battery-operated and field-powered applications across diverse consumer and automotive industries.
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
Department for Business and Trade
The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | Connect with the UK Invest in the UK: Access free, confidential advice and support on your inward investment journey. Buy from the UK: The UK’s thriving life sciences sector has a lot to offer the world, from innovative products to expert services. Export from the UK: We Provide insights, training, events, finance and expert support so exporters can realise the full benefits of internationalising. Innovate with the UK: Connect into our networks to partner with UK academia, research institutes, centres of excellent and spinouts. Talk to us today and continue connecting with the UK in your home country via our teams based in over 100 international markets. | This UK government department specialises in helping UK businesses and bringing investment into the UK.
DeepLife
DeepLife is a biotech company transforming drug development through artificial intelligence and digital twin technology. Our platform leverages an AI-driven engine that maps cell-type-specific networks, utilizing over 100 million harmonized single-cell omics data points to identify targets and analyze regulatory networks with unprecedented precision. Our modular platform rests on three pillars: a comprehensive data foundation, sophisticated target identification algorithms, and advanced drug repurposing capabilities. We deploy this technology both for our internal drug repurposing pipeline and for partner collaborations focusing on target identification, derisking assets, indication expansion, and disease relevance assessment. This approach dramatically accelerates development by finding new applications for compounds with established safety profiles. Supported by $10M Series A funding and strategic collaborations with partners like Beiersdorf on skin diseases and aging, DeepLife simulates drug effects at the cellular level, opening doors to novel therapies. Our AI-driven simulations and multi-omics analytics enable pharmaceutical partners to develop precision treatments that are more targeted, faster, and cost-effective in addressing complex medical challenges.
Decode Cure Limited
Decode Cure Limited specializes in rapid microbial identification using proprietary genomics and big data analytics for clinical, environmental, and research applications. Decode Cure’s mission is to reduce mortality rates and medical expenses associated with complex diseases by enabling faster and more accurate diagnoses. Our system can rapidly identify pathogens that cause respiratory tract illness, other complex human diseases, like cancer, Alzheimer’s disease and environmental issues. Decode Cure’s products have earned recognition and validation through respected external quality programs like College of American Pathologists and Quality Control for Molecular Diagnostics. Our solutions are instrumental in analyzing diverse samples for government, non-profit, and for-profit organizations, addressing critical health and environmental challenges.
Cogitars GmbH
We are dedicated to delivering expert statistical support to pharmaceutical and biotechnology companies throughout every phase of clinical development, from early-stage trials to post-market studies. Since our establishment in 2013, we have amassed over a decade of in-depth experience, becoming a trusted partner to a wide range of global clients. With our extensive expertise, we have contributed significantly to the success of countless clinical trials by ensuring the highest standards of statistical rigor, precision, and compliance. We take pride in our collaborative approach, tailoring our services to meet the unique needs of each client and project, and helping to bring innovative therapies to patients worldwide. We offer expertise in the following areas: • Biostatistical Strategic Consulting: Providing tailored statistical guidance to optimize clinical trial design, execution, and outcomes • Bayesian Statistics: Leveraging advanced Bayesian methodologies to enhance decision-making and trial efficiency. • Adaptive Trial Designs: Designing and implementing innovative, flexible trial structures that allow for modifications based on interim data • Real-Time Data Monitoring: Utilizing their cutting-edge visualization platform, cogiviz, to enable dynamic and intuitive tracking of trial progress and data insights • Comprehensive Trial Reporting: Delivering detailed and robust trial analyses to support regulatory submissions and ensure compliance with global standards • Full Programming: Comprehensive data processing, statistical analysis, and report generation, ensuring compliance with regulatory standards and reproducibility.
China Chamber of International Commerce
China Chamber of International Commerce, or CCOIC, was established in 1988 with the approval of the State Council of the People’s Republic of China. Affiliated to China Council for the Promotion of International Trade (CCPIT), CCOIC is a nationwide chamber of commerce comprised of enterprises, groups and other business organizations that are engaged in international commercial activities in China. CCOIC also represents China in participating in the work of International Chamber of Commerce (ICC) with the name of ICC China. CCOIC adopts a membership system and its main responsibilities include: promoting economic and trade exchanges and cooperation between China and foreign countries; reflecting interest appeal of enterprises to international organizations and government departments of China and foreign countries on behalf of Chinese business community; participating in constitution and promotion of international trade rules; facilitating enterprises to participate in international competition and cooperation; safeguarding legitimate rights of its members, and actively advocating social responsibility and public welfare among business circles. By the end of 2021, CCOIC has 301,000 member enterprises, including most central SOEs, national financial institutions, a large number of well-known private enterprises and foreign-funded enterprises. CCOIC has become one of the most influential business associations in China. With the aim of building a hub-like chamber of commerce, CCOIC has institutional cooperation with other business associations from home and abroad, and provides services for its members and other enterprises including international exchange, industrial cooperation, legal advice, market information, exhibition planning, project investment and training. | China Chamber of International Commerce, or CCOIC, was established in 1988 with the approval of the State Council of the People’s Republic of China. Affiliated to China Council for the Promotion of International Trade (CCPIT), CCOIC is a nationwide chamber of commerce comprised of enterprises, groups and other business organizations that are engaged in international commercial activities in China. CCOIC also represents China in participating in the work of International Chamber of Commerce (ICC) with the name of ICC China. CCOIC adopts a membership system and its main responsibilities include: promoting economic and trade exchanges and cooperation between China and foreign countries; reflecting interest appeal of enterprises to international organizations and government departments of China and foreign countries on behalf of Chinese business community; participating in constitution and promotion of international trade rules; facilitating enterprises to participate in international competition and cooperation; safeguarding legitimate rights of its members, and actively advocating social responsibility and public welfare among business circles. Up to now, CCOIC has 351,000 member enterprises, including most central SOEs, national financial institutions, a large number of well-known private enterprises and foreign-funded enterprises. CCOIC has become one of the most influential business associations in China. With the aim of building a world-class chamber of commerce with Chinese characteristics, CCOIC has institutional cooperation with other business associations from home and abroad, and provides services for its members and other enterprises including international exchange, industrial cooperation, legal advice, market information, exhibition planning, project investment and training.
CH Kilger, Patent & Trademark Attorneys
An International Approach With its head office in Berlin, branch offices in Munich and Buenos Aires CH KILGER offers a truly international approach providing a global IP service to its clients. The Munich office serves also for the preparation of the frequent oral proceedings CH KILGER takes part in. In Buenos Aires CH KILGER coordinates its Latin America services. The patent attorneys are highly specialized and strategic in their approach. A Wingspan of Expertise CH KILGER provides IP services ranging from trademark and patent prosecution, patent infringement and litigation, due diligence work, freedom-to-operate analyses, to opinion work and IP-sales/licensing transactions. CH KILGER can assist you in all technical areas such as the chemical, electrical, nanotechnology, food, biotechnology and pharmaceutical or the engineering fields. Strong scientific backgrounds, as well as years of legal experience working with the European Patent Office, the Latin American patent offices, top-tier international law firms and in-house counsel, mean the CH KILGER lawyers understand their technical, business, and legal goals. Our interdisciplinary approach leads to best possible synergies for our clients. Our Clients and Colleagues CH KILGER represents an international clientele of inventors as well as investors working with the most recent high-tech technologies. The clients range from multinational pharmaceutical corporations to start ups in various fields such as nanotechnology, microfluidics, polymer chemistry and biotechnology. Clients and colleagues have praised the firm for its exquisite work.
Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. | Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Centre for Translational Stem Cell Biology
Centre for Translational Stem Cell Biology (CTSCB) provides Hong Kong with an opportunity to excel in scientific and medical research. A team of top-notch scientists and clinicians from the University of Hong Kong and the University of Cambridge collaborates to elevate stem cell technology to new heights. By leveraging a pioneering patented technology, Expanded Potential Stem Cells (EPSCs), CTSCB is dedicated to advancing fundamental research and translating discoveries into regenerative medicine, organ transplantation and genomic medicine for the benefit of people worldwide. CTSCB primarily focuses on producing mature and functional cells for regenerative medicine with the patented technology, enabling in-depth study of immune disease mechanism, and expediting the development of antiviral, anti-ageing natural products and antibody drugs. Our vision is to translate medical discoveries and homegrown technologies into applications that not only serve medical and biotechnological purposes but also extend to the agricultural sector, fostering the growth of innovation and technology. | Imagine a future where healthcare is transformed by cutting-edge stem cell technology. Centre for Translational Stem Cell Biology (CTSCB), a collaboration between the University of Hong Kong and the University of Cambridge, supported by the Innovation and Technology Commission, is at the forefront of making this vision a reality. Leveraging patented Expanded Potential Stem Cell (EPSC) technology, we can create any cell type, both embryonic and extra-embryonic, offering immense potential for regenerative medicine and therapeutic applications. Our research focuses on intelligent drug screening, precision medicine and cell-based therapies. We develop next-generation stem cell technology that improves patient outcomes and enhances quality of life. Our drug screening platforms support pharmaceutical and health supplement companies in streamlining their development processes using multicellular organoid systems and personalized disease modelling. We also explore health and cosmetic products derived from EPSC technology, with interests in product co-development to address various health issues. By attracting top global talent and fostering innovation, CTSCB is well-positioned to enhance therapeutic applications and promote longevity. Through our innovative research and commitment to excellence, CTSCB aims to lead the way in revolutionary healthcare solutions for generations to come.